NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2016.80 -1.00 (-0.05%)

58.12% Gain from 52W Low

424.4K NSE+BSE Volume

NSE 23 Sep, 2025 3:31 PM (IST)

56,914.3

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Glenmark Pharmaceuticals Ltd. is on 26 Sep 2025 for the purpose of Interim Dividend See details

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

16 Aug 2016

2016.80

-0.05%

Glenmark Q1FY17 Update 16Aug2016

Buy: Glenmark Pharmaceuticals Ltd.

Target

Phillip Capital

Key highlights: Revenues were 3% below our estimates to Rs 19.43bn (+18% yoy). While US sales of US$ 104mn (+24% yoy) was in line of our estimates and Domestic formulations outpaced industry growth, the weak show by Latin America markets led to miss in sales estimates. Visible pricing pressure in US & higher employee cost caused 270bps negative surprise in operating margin at 19.5% (estimated 22.2%) that resulted in 15% below expected EBITDA at Rs 3.79bn. Thanks to forex gain of Rs700mn that supported PAT at Rs 2.18bn (10% below estimated). However, the tax rate was higher at 35% (vs 25% normal). The core earnings (adjusted forex gain and abnormal taxes) were 18% below expectation.Phillip Capital now value GNP at Rs 1000 i.e.19x FY18 EPS, implying 18% potential upside. Re?iterate BUY with a lowered TP of Rs 1000.

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2019.0

Glenmark Pharmaceuticals Ltd.

16 Aug 2016

2016.80

-0.05%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 17.9% YoY to | 1943.1 crore (I-direct estimate: | 2021.9 crore) mainly due to 24.4% YoY growth in the US to | 698.2 crore (I-direct estimate: | 698.8 crore). India business grew 10.4% YoY to | 513.8 crore (I-direct estimate: | 520.2 crore) EBITDA margins declined 230 bps YoY to 19.5% (I-direct estimate: 21.1%) due to lower gross margins, higher employee cost. EBITDA rose mere 5.5% YoY to | 379.1 crore (I-direct estimate: | 427.0 crore)...

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Glenmark Pharmaceuticals Ltd.

16 Aug 2016

2016.80

-0.05%

Glenmark - 1QFY17 Result Update

Hold: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Reliance Securities

Glenmark Pharmaceuticals' (GNP) Sales, EBITDA & PAT stood at Rs19.4bn, Rs3.8bn & Rs2.2bn, respectively in 1QFY17. Revenue from US business (~37% of sales) rose 18% yoy to US$104mn in 1QFY17 (vs. US$97mn in Q4FY16 & US$89mn in Q1FY16) due to new product approvals. Revenue from India business (~27% of sales) grew by just 10% yoy to Rs5.1bn due to adverse impact of New Pricing Policy and ban on several fixed dose combinations. Revenue from semi-regulated markets (10% of sales) grew 23% yoy due to strong growth in Russia (50% yoy in CC terms). LatAm (~8% of sales) degrew 29% yoy due to negligible contribution from Venezuela and weak performance in Brazil...

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

13 Aug 2016

2016.80

-0.05%

Glenmark Pharma: Operational performance in line; PAT beat due to for

Neutral: Glenmark Pharmaceuticals Ltd.

Motilal Oswal

Glenmark Pharma (GNP) reported revenues of INR18.8b (+16% YoY; 2% miss), driven by strong growth in the US, Europe, ROW and API businesses. EBITDA margin came in at 17%, in line with our estimate. Reported PAT of INR2.3b (+24% YoY) was 44% above...

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Glenmark Pharmaceuticals Ltd.

02 Jun 2016

2016.80

-0.05%

Glenmark Pharmaceuticals Ltd.

Buy: Glenmark Pharmaceuticals Ltd.

Ashika Research

off the EBITDA was ~Rs. 460 crore i.e. 20% of revenues. Adjusted for these, margins improved 310bps. Adjusted net profit grew Avg. daily volume (1yr. on NSE)...

Glenmark Pharmaceuticals Ltd. has gained 33.14% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

16 May 2016

2016.80

-0.05%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Revenues grew 28.5% YoY to | 2281.3 crore (I-direct estimate: | 1849.6 crore) mainly on account of robust growth across geographies. The company witnessed 21.6% YoY growth in the US to...

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2019.0

Glenmark Pharmaceuticals Ltd.

16 May 2016

2016.80

-0.05%

Glenmark Q4FY16 Update 16May2016

Buy: Glenmark Pharmaceuticals Ltd.

Target

Phillip Capital

ROW (+36%) and LatAm (+34%) sales. US sales of US$ 97mn were inline with our estimates.CoreoperatingmarginadjustingforforexlossofRs840mnandonetime SitagliptinrelatedlitigationcostofRs650mn)compressedby~260bpsyoyto19.8%...

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Glenmark Pharmaceuticals Ltd.

30 Jan 2016

2016.80

-0.05%

Glenmark 30Jan2016

Buy: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Phillip Capital

However, margin performance was just about in line as improving revenue mix towards bettermargindomestic/USbusinessraisedEBITDAmarginsby80bpsto22.6%.Ledbylower salesandhighertaxincidenceof33%,PAT(adjustedforforexlossofRs270mn)was19%...

Glenmark Pharmaceuticals Ltd. has gained 23.22% in the last 3 Months

Is Glenmark Pharmaceuticals Ltd. worth buying?

571 Votes:

Buy 79.33%

Sell 13.66%

Hold 7.01%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf